Based on the results of the DreamSeq study, the combination of ipilimumab and nivolumab is most appropriate as first-line treatment in the majority of BRAF mutant–positive patients with newly metastatic disease. This study demonstrated improved overall survival with the combination of ipilimumab and nivolumab vs a BRAF-MEK therapy.
According to the NCCN guidelines, ipilimumab as a single agent is not recommended as first-line therapy. Two clinical trials have demonstrated the superiority nivolumab-ipilimumab combination therapy compared with ipilimumab monotherapy in patients with BRAF-mutant disease. Combination therapy has also been shown to improve progression-free survival compared with single-agent nivolumab.
Learn more about the treatment of metastatic melanoma.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Adil Daud. Fast Five Quiz: Metastatic Melanoma - Medscape - Mar 15, 2023.